Indaptus Therapeutics (INDP) Other Working Capital Changes (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Other Working Capital Changes of -$119319.0 for Q1 2026, down 1524.27% year-over-year from $8377.5 in Q1 2025, and down 106.26% quarter-over-quarter from $1.9 million in Q3 2025.
Indaptus Therapeutics (INDP) Other Working Capital Changes (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at -$119319.0 for Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 1524.27% year-over-year to -$119319.0; the TTM figure through Mar 2026 stood at $964759.0 (up 137.2% YoY), while the FY2024 annual figure was $81944.0, down 87.96% from the prior year.
- Other Working Capital Changes for Q1 2026 stood at -$119319.0, down from $1.9 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $1.9 million in Q3 2025, with the low at -$814553.0 in Q2 2025.
- The 5-year median for Other Working Capital Changes is -$146496.0 (2024), against an average of $153062.3.
- Peak annual rise in Other Working Capital Changes reached 1679.86% in 2023, while the deepest fall reached 2377.79% in 2023.
- Indaptus Therapeutics' Other Working Capital Changes stood at -$16477.0 in 2022, then slumped by 2377.79% to -$408265.0 in 2023, then slumped by 44.98% to -$591885.0 in 2024, then surged by 422.02% to $1.9 million in 2025, then plunged by 106.26% to -$119319.0 in 2026.
- Business Quant data shows INDP's Other Working Capital Changes at -$119319.0 in Q1 2026, $1.9 million in Q3 2025, and -$814553.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Indaptus Therapeutics | 145.16 Mn | 133.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -249,085.00 |
| Jun 30, 2026 | -249,085.00 |
| Jun 30, 2026 | -249,085.00 |
| Mar 31, 2026 | -119,319.00 |
| Mar 31, 2026 | -119,319.00 |
| Mar 31, 2026 | -119,319.00 |
| Sep 30, 2025 | 1.91 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Sep 30, 2025 | 1.91 Mn |
| Jun 30, 2025 | -814,553.00 |
| Jun 30, 2025 | -814,553.00 |
| Jun 30, 2025 | -814,553.00 |
| Mar 31, 2025 | -7,346.00 |
| Mar 31, 2025 | -7,346.00 |
| Mar 31, 2025 | -7,346.00 |
| Dec 31, 2024 | -591,885.00 |
| Dec 31, 2024 | -591,885.00 |
| Dec 31, 2024 | -591,885.00 |
| Sep 30, 2024 | -173,673.00 |
| Sep 30, 2024 | -173,673.00 |